Congratulations to our Research Fellow Dr Crispin and colleagues as Hansa Medical who take their method of improving anti-cancer therapy toward clinical trials, marking the the next steps to improve cancer treatments.
Dr Max Crispin holds the Against Breast Cancer Fellowship in Cancer Therapeutics at Oriel College, Oxford, which was awarded to support Dr Crispin’s work on antibody engineering and the development of novel cancer therapies. Together with his colleague, Dr Chris Scanlan, they invented a technology to enhance anti-cancer drugs and founded Immago Biosystems to pursue its development. The technology involves enzyme-based antibody enhancement of anti-cancer antibodies. We are proud to share the news that Hansa Medical have acquired Immago Biosystems and verified the research findings by combining its lead candidate, IdeS, with approved anti-cancer antibodies in cancer models.
By combining IdeS with a therapeutic antibody, the efficacy of the antibody is significantly enhanced with maintained specificity. Potentially, this means that presently available antibody based cancer therapies could be made more effective”
Dr Christian Kjellman, Senior Vice President, R&D at Hansa Medical AB
Against Breast Cancer aims to support the early development of novel cancer therapies and last year awarded Dr Crispin and his colleagues at the Oxford Glycobiology Institute a research grant to help them achieve their next breakthrough. You can read more about this work here.